20-F: Meihua International Medical Technologies Reports Financial Results

Meihua International Medical Technologies Co., Ltd. reported a significant decrease in revenues and net income for the fiscal year ended December 31, 2025, primarily due to reduced sales volume and increased market competition.

Summary

• Meihua International Medical Technologies Co., Ltd. experienced a substantial decline in revenues, falling by approximately $35.12 million to $61.79 million for the year ended December 31, 2025, compared to $96.91 million in the prior year.
• Net income also saw a significant decrease of about $4.06 million, or 37%, to $6.78 million for the fiscal year 2025, down from $10.84 million in 2024.
• The primary driver for this downturn was a reduction in sales volume for disposable medical devices, which decreased by approximately 43% year-over-year, attributed to increased market competition and a slowdown in market demand.
• Operating expenses also decreased, with selling expenses down by 36% and general and administrative expenses down by 59%, largely due to reduced business activities and a reversal of legal costs.
• The company's Class A Ordinary Shares were delisted from Nasdaq in December 2025 due to failure to meet minimum bid price and publicly held shares requirements, and now trade on the OTC Markets.
• In recent private placements, the company raised approximately $15.2 million in October 2025 and $1.32 million in December 2025 from non-U.S. investors.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the significant decline in revenues and net income, coupled with the delisting from Nasdaq and identified material weaknesses in internal controls.

Positives

• Selling expenses decreased by approximately $2.41 million (36%) to $4.22 million in 2025, mainly due to reduced transportation, entertainment, and conference expenses reflecting lower business activity.
• General and administrative expenses decreased significantly by approximately $4.57 million (59%) to $3.21 million in 2025, primarily due to a reversal of approximately $1.35 million in legal costs.
• The company has a history of over 30 years in the medical device industry and holds international CE certification and ISO 13485 certification, with FDA registration for over 20 products.
• The company has a broad distribution network, with 4,409 domestic distributors and 403 exporting distributors, and a direct sales force of 81 employees and 5,385 independent sales agents.
• The company is developing a medical industrial park in Hainan Free Trade Port, with Phase I expected to generate revenue following completion in July 2026, and has secured three tenants for this park.

Negatives

• Revenues decreased by approximately $35.12 million (36%) to $61.79 million in 2025 from $96.91 million in 2024.
• Net income decreased by approximately $4.06 million (37%) to $6.78 million in 2025 from $10.84 million in 2024.
• Gross profit margin decreased from 34% in 2024 to 31% in 2025.
• The quantity of disposable medical devices sold decreased by approximately 43% in 2025 compared to 2024.
• The company's Class A Ordinary Shares were delisted from Nasdaq in December 2025 and now trade on the OTC Markets, which may limit liquidity and increase price volatility.
• The company has identified material weaknesses in its internal control over financial reporting due to insufficient accounting personnel with knowledge of U.S. GAAP and SEC reporting rules.

Risks

• The company's Class A Ordinary Shares are currently quoted on the OTC markets rather than listed on a national securities exchange, which may limit liquidity and increase price volatility.
• The company faces intense competition in the medical device industry from both domestic and international companies, some of which have greater resources.
• The company is dependent on its top customers, and a loss of these customers could adversely affect its financial performance.
• Changes in PRC laws and regulations, including those related to cybersecurity, data privacy, and foreign investment, could materially impact the company's business.
• The company may be subject to intellectual property infringement claims, which could be expensive to defend and disrupt its business.
• The company has not purchased any property insurance or business interruption insurance, exposing it to significant costs and business disruption in the event of uninsured losses.

Future Outlook

The company plans to expand its business by increasing capacity and diversifying product offerings to provide tailored one-stop services. This expansion may require additional capital through equity financing. The company is also developing a medical industrial park in Hainan Free Trade Port, with Phase I expected to generate revenue following completion in July 2026, though this is subject to market conditions and potential risks.

Management Comments

• The decrease in revenue from sale of disposable medical devices was primarily attributable to reduction in sales volume because of increasing market competition and reduction in market demand.
• Our management believes that it is more likely than not that the results of future operations will generate sufficient taxable income to realize the deferred tax assets as of December 31, 2025 and 2024.

Industry Context

StockSavvy.ai notes that Meihua International's revenue decline and delisting from Nasdaq reflect broader challenges faced by some China-based companies operating in competitive global markets, particularly in the medical device sector. The company's strategy to focus on a 'one-stop service' model and its geographical advantage in Touqiao Town are key differentiators, but the overall market conditions and increased competition are significant headwinds.

Comparison to Industry Standards

• Meihua International's revenue of $61.79 million in 2025 is significantly lower than its 2024 revenue of $96.91 million, indicating a substantial market share contraction or demand reduction.
• The company's gross profit margin of 31% in 2025 is below the industry average for medical device manufacturers, which typically ranges from 40-60%, suggesting pricing pressures or higher cost of goods sold.
• The company's R&D investment of $2.38 million in 2025 represents approximately 3.8% of its total revenue, which is lower than the industry benchmark of 5-10% for medical device companies focused on innovation and growth.
• The delisting from Nasdaq and subsequent trading on OTC Markets indicates a potential lack of investor confidence or failure to meet exchange listing requirements, which is a negative indicator compared to peers listed on major exchanges.

Management Changes

Corporate Governance

Legal Proceedings

• A legal proceeding, Zhu Cheng v. Jiangsu Yada Technology Group Co., Ltd., et al., was filed, claiming joint and several liability for $2.3 million plus interest. The Yangzhou Economic and Technological Development Zone Peoples Court initially ruled in favor of Zhu Cheng, ordering Jiangsu Yada to pay RMB 17 million plus interest. However, on December 12, 2025, the Yangzhou Intermediate Peoples Court revoked the original judgment, dismissed Zhu Cheng's lawsuit, and allocated litigation costs, making the ruling final.

Related Party Transactions

• Sales to Yangzhou Meihua Import and Export Co., Ltd. (controlled by Mr. Kai Liu, son of shareholder Yongjun Liu) amounted to $831,327 in 2025, $768,553 in 2024, and $416,441 in 2023.
• As of December 31, 2025, accounts receivable from Yangzhou Meihua Import and Export Co., Ltd. were $1,499,525.
• Advances to related parties included $11,466,326 due from Hainan Guoxie and $10,009,867 due from Jiangsu Guomai as of December 31, 2025.
• The company advanced $6,849,972 to Zhongxiangxin in 2024, which was fully collected in March 2025.
• The company advanced $10,190,726 to Hainan Guoxie in 2024, which is interest-free and will be converted into a capital injection.
• The company advanced $1,275,600 to Hainan Guoxie in 2025.
• The company advanced $10,438,861 to Jiangsu Guomai in 2025 with a fixed interest rate of 2.35%.

Stakeholder Impact

• Shareholders may experience reduced returns due to the significant decrease in revenues and net income, and the delisting from Nasdaq impacting share liquidity and price volatility.
• Employees may face uncertainty due to the company's financial performance and the identified material weaknesses in internal controls.
• Suppliers may experience changes in order volumes and payment terms due to the company's reduced sales and potential cash flow constraints.
• Creditors may face increased risk given the company's financial performance and reliance on short-term borrowings.

Next Steps

• The company intends to expand its business by increasing capacity and diversifying product offerings.
• Phase I of the medical industrial park development in Hainan Free Trade Port is expected to begin generating revenue following completion in July 2026.
• The company continues to evaluate potential opportunities in AI technologies for online health consultation services and surgical robotic assisted surgery (RAS) systems.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, with revenues and net income declining substantially in 2025. The delisting from Nasdaq and subsequent trading on the OTC Markets, coupled with identified material weaknesses in internal controls, indicate significant operational and financial risks. While the company is pursuing new capital raises and has a diversified product portfolio, the current market conditions and competitive pressures, combined with the company's financial trajectory, suggest a 'sell' recommendation for investors.

Keywords

Meihua International Medical Technologies, Form 20-F, SEC Filing, Medical Devices, Financial Results, Revenue Decline, Net Income Decrease, Nasdaq Delisting, OTC Markets, China, Healthcare Industry